By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug...
The Food and Drug Administration has approved Signos' glucose monitoring system specifically designed for weight loss, marking a significant develo...
A recent survey conducted by the Business Group on Health indicates that employers are preparing for a substantial rise in healthcare costs, projec...
An opinion piece argues that competition, rather than government mandates, is the key to lowering drug prices in the U.S. President Trump signed an...
Pleural Dynamics, a Minnesota-based medical device company, has completed enrollment for 'The ACES Study for Aseptic Pleural Effusions.' This post-...
Recent research highlights the significant impact of hearing aids on reducing dementia risk, particularly when used before the age of 70. The study...
Novo Nordisk is awaiting FDA approval for an oral 25 mg dose of semaglutide, the active ingredient in Wegovy, aimed at weight loss. The company has...
The FDA is expected to make a decision in the fourth quarter regarding the approval of an oral 25 mg dose of semaglutide, the active ingredient in ...
Eli Lilly and Novo Nordisk are preparing to launch new oral medications for obesity treatment, with pricing expected to be similar to their existin...
GoodRx has announced a collaboration with Novo Nordisk to offer Ozempic and Wegovy pens at a reduced price of $499 per month for eligible self-payi...